GLOX DEVELOPMENT PROGRAM
The Glox Development Program targets pathogenic bacteria related to Anti-Microbial Resistance (AMR)
Glox Therapeutics’ engineered protein bacteriocins will represent an entirely new class of therapeutic antibiotics. These targeted narrow-spectrum antibiotics will enable specific bacterial pathogens to be eliminated without collateral damage to the normal microbiota which is essential for optimum health. Glox will create engineered protein antibiotics to target the following Gram-negative pathogens from the WHO Critical Priority list:
- Glox001: targeting P. aeruginosa in ventilator-associated pneumonia (VAP).
- Glox002: targeting K. pneumoniae in ventilator-associated pneumonia (VAP).
- Future products will include A. baumannii, E. coli and potentially other members of the Enterobacteriaceae